Immune B-cells that contain the receptor protein CD226 may play a role in the development and clinical manifestations of primary Sjögren’s disease, making CD226 a possible target for future treatments, a study reports. Data indicated that people with Sjögren’s had proportionally more CD226-positive B-cells in their bloodstream than their healthy counterparts. The prevalence of these […] The post B-cells containing CD226 may be Sjögren’s biomarker, therapy target appeared first on S...| Sjogren's Disease News – The Web's Daily Resource for Sjogren's Disease News
Geoff’s Translations The GIST Redefining Chronic Pain Andreas Goebel of the Pain Research Institute at the University of Liverpool has been trying to redefine how we think about chronic pain for about 20 years. His journey began with a 2010 complex regional pain syndrome (CRPS) paper, which proposed that […] The post Fibromyalgia – Are it (and ME/CFS) Autoimmune Diseases? appeared first on Health Rising.| Health Rising
Geoff’s Narrations The GIST The Blog We’re back to the B-cells, and that brings us back to the Charité 3rd International ME/CFS and long COVID Conference. B and T-cells are the two main players in the adaptive or late immune response. They’re the cells we depend on to wipe […] The post Has the Right B-cell Depleting Drug Been Found for ME/CFS? Daratumumab Shines in Pilot Study appeared first on Health Rising.| Health Rising
Uplizna reduces several subsets of immune B-cells that are linked to relapses in people with neuromyelitis optica spectrum disorder, data show.| Neuromyelitis News
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News